Tokyo, Apr 18, 2007 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. announced today that bevacizumab (genetical recombination), a humanized anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody (brand name: Avastin(R) for intravenous infusion 100mg/4mL or 400mg/16mL) obtained approval today from the Japanese Ministry of Health, Labour and Welfare for the treatment of advanced or refractory colorectal cancer who is not the candidate for the curative operation.
